Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.

    ... (45.5% vs. 11.8%, P<0.001). IDH2 mutation was a poor prognostic factor for overall survival in patients with lower-risk MDS, based on international prognosis scoring system (IPSS), FAB classification, WHO ...

    Research Article last updated 10/22/2013 - 12:48pm.

  2. Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.

    ... indications for SCT in MDS remains a difficult task. The International Prognostic Scoring System (IPSS) serves as a guideline for therapeutic ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

    ... of myelodysplastic syndromes (MDS), including the International Prognostic Scoring System (IPSS), do not fully reflect the molecular heterogeneity of the ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

    ... of any French-American-British (FAB) subtype and an International Prognostic Scoring System (IPSS) score > or = 0.5. The primary end point was ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Current therapeutic approaches for patients with myelodysplastic syndromes.

    ... patients' specific clinical features, predominantly their prognostic subgroups, age and performance status. Guidelines for management of ... in the US and in other countries. For lower risk disease (International Prognostic Scoring System Low and Intermediate-1) therapy is ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes.

    ... consisting of 10 microRNAs was closely associated with International Prognostic Scoring System (IPSS) risk category permitting discrimination ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes

    ... varies with MDS risk. For those with low/intermediate-1 International Prognostic Scoring System (IPSS) risk, non-HSCT treatments may be ...

    Research Article last updated 02/08/2013 - 7:58am.

  8. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update

    ... been shown to be active in numerous studies including International Prognostic Scoring System (IPSS) intermediate-1 to high risk patients, in ...

    Research Article last updated 11/05/2012 - 9:34am.

  9. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

    ... had intermediate-2 or high-risk MDS according to the International Prognostic Scoring System (IPSS). Progression to more advanced disease ...

    Research Article last updated 11/05/2012 - 8:57am.

  10. TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression.

    ... marrow (BM) samples from 55 consecutive patients with International Prognostic Scoring System low risk (n = 32) or intermediate-1 risk (n = 23) ...

    Research Article last updated 10/11/2011 - 5:58pm.